VB-201

DRUG2 trials

Sponsors

Vascular Biogenics Ltd. operating as VBL Therapeutics, Priscilla Hsue, MD

Conditions

Active Plaque PsoriasisCardiovascular DiseaseHIV InfectionInflammation

Phase 1

Immunomodulation Using VB-201 to Reduce Arterial Inflammation in Treated HIV - VITAL HIV Trial

WithdrawnNCT04939311

Priscilla Hsue, MDCardiovascular Disease, HIV Infection, Inflammation

Start: 2022-07-01End: 2027-07-01Updated: 2022-09-15

Phase 2

Study to Assess VB-201 in Patients With Psoriasis

CompletedNCT01001468

Vascular Biogenics Ltd. operating as VBL TherapeuticsActive Plaque Psoriasis

Start: 2009-12-31End: 2011-07-31Updated: 2011-11-16